The BMJ has issued the first international living guidelines for the prevention of cardiovascular (CV) and kidney complications in type 2 diabetes (T2D), tying treatment recommendations to a patient’s individual cardio-renal risk profile.

Part of the Rapid Recommendations initiative, the guidance represents a dynamic, continuously updated framework for clinicians worldwide.

The recommendations stem from a systematic review and network meta-analysis of nearly 500,000 adults with T2D across 869 randomized trials, covering 63 drugs and 26 outcomes.

The panel warned that undertreatment of high-risk patients and overtreatment of low-risk patients are both common in real-world practice.